Podcasts about american brain tumor association

John and Paige talk with photographer/tour manager/many-hat-wearer Ashley Gellman about life on the road and at home. Ashley has worked with artists like Bartees Strange, Jamie xx, Jonas Brothers, boygenius, and is currently on the road with Lucy Daucus. She's a larger-than-life personality, and she breaks down her life on the road, her upbringing as an independent kid doing her own thing, her relationships with the early artists she worked with, found family amidst her touring peers, and how to capture the best shot without being in the way. Amidst a whirlwind of travel and work, Ashley talks in depth about how she's grown to embrace being home, and how she balances the "all-in" touring lifestyle with the calmer vibes of being back in Philadelphia. If you can manage to pin her down, Ashley does do photo shoots for hire when she can, so follow her on IG.  On Sunday, May 18th, the 12th annual Brain Fest is happening at Fringe Bar in Philadelphia from 5pm to midnight. Brain Fest raises money and awareess for treatment of brain tumor, with all the proceeds going to the American Brain Tumor Association. Performers include Adventure Lost, The Lunar Year, Alright Junior, Trash Boy, Erin Fox and the Hounds, Annalise Curtim, and more. More info available at their event posting and at the ABTA donation site. 

Send us a textDr. Laura Aguilar, MD, Ph.D. is Chief Medical Officer at Diakonos Oncology ( https://www.diakonosoncology.com/ ), a clinical stage immuno-oncology company dedicated to revolutionizing cancer immunotherapy and focusing on difficult-to-treat indications, including glioblastoma. Dr. Aguilar, a physician-scientist and biotech entrepreneur, has over 20 years of experience in clinical and regulatory development of complex biologics for cancer with a focus on solid tumors including glioblastoma and pancreatic cancer.Dr. Aguilar was co-founder of Advantagene (now Candel Therapeutics) where she served as chief medical officer. She was a leader in the company's strategic development from inception to successful IPO, and she oversaw the company's clinical development portfolio of viral immuno-oncology products in four disease indications.Dr. Aguilar also was an attending physician at the Dana Farber Cancer Institute and Boston Children's Hospital and associate director of the Harvard Gene Therapy Initiative at Harvard Medical School. She currently serves on several boards including the Board of the American Brain Tumor Association.Dr. Aguilar earned her MD and Ph.D. in microbiology and immunology from Baylor College of Medicine. She completed her clinical residency in pediatrics and fellowship in pediatric hematology-oncology at Texas Children's Hospital.#LauraAguilar #DiakonosOncology #ChiefMedicalOfficer #Glioblastoma #PancreaticAdenocarcinoma #Immunooncology #Immunotherapy #DendriticCells #MajorHistocompatibilityComplex #CrossPresentation #DoubleLoading #Interferon #Melanoma #Cancer #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #Podcasting #ViralPodcast #STEM #Innovation #Science #Technology #ResearchSupport the show

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/HZS865. CME/MOC/AAPA credit will be available until December 21, 2025.Capitalizing on Personalized Care in IDH-Mutant Gliomas: Expert Guidance on the Use of Biomarker Testing and Targeted Therapies in Real-World Settings In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Brain Tumor Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Servier Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/HZS865. CME/MOC/AAPA credit will be available until December 21, 2025.Capitalizing on Personalized Care in IDH-Mutant Gliomas: Expert Guidance on the Use of Biomarker Testing and Targeted Therapies in Real-World Settings In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Brain Tumor Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Servier Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/HZS865. CME/MOC/AAPA credit will be available until December 21, 2025.Capitalizing on Personalized Care in IDH-Mutant Gliomas: Expert Guidance on the Use of Biomarker Testing and Targeted Therapies in Real-World Settings In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Brain Tumor Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Servier Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/HZS865. CME/MOC/AAPA credit will be available until December 21, 2025.Capitalizing on Personalized Care in IDH-Mutant Gliomas: Expert Guidance on the Use of Biomarker Testing and Targeted Therapies in Real-World Settings In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Brain Tumor Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Servier Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/HZS865. CME/MOC/AAPA credit will be available until December 21, 2025.Capitalizing on Personalized Care in IDH-Mutant Gliomas: Expert Guidance on the Use of Biomarker Testing and Targeted Therapies in Real-World Settings In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Brain Tumor Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Servier Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/HZS865. CME/MOC/AAPA credit will be available until December 21, 2025.Capitalizing on Personalized Care in IDH-Mutant Gliomas: Expert Guidance on the Use of Biomarker Testing and Targeted Therapies in Real-World Settings In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Brain Tumor Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Servier Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/HZS865. CME/MOC/AAPA credit will be available until December 21, 2025.Capitalizing on Personalized Care in IDH-Mutant Gliomas: Expert Guidance on the Use of Biomarker Testing and Targeted Therapies in Real-World Settings In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Brain Tumor Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Servier Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/HZS865. CME/MOC/AAPA credit will be available until December 21, 2025.Capitalizing on Personalized Care in IDH-Mutant Gliomas: Expert Guidance on the Use of Biomarker Testing and Targeted Therapies in Real-World Settings In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Brain Tumor Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Servier Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

I met up with my friend Jace Miller at Silk City on Spring Garden St. for this latest episode of TatD. A revered Philly diner - a little more on the upscale side than your typical greasy spoon - Silk City has vibe to spare. It's also a spot that hosts full-on rock shows and other eclectic musical events in its back room. You could hear someone sound checking for a show around the time we sat down to catch up on a Wednesday at 5:30 - that no-man's land between the end of the afternoon and the beginning of the evening. Over a beef short rib grilled cheese (me) and a meatball salad special (him), we got into all kinds of topics from the panic of thinking your cat ran out the front door during a washing machine delivery, to tales of sadly departed former bosses in the concert booking industry (RIP Bryan Dilworth), to realizing your band sounds better with fewer people in it.Since the early aughts, Jace has been the frontman and band leader of Alright Junior, one of Philly's most consistent alt-rock juggernauts. The band has an impressive tenure as well as an impressive resume of prestigious opening gigs, having shared stages with Incubus, Toadies, Young The Giant, Cake, and many more. Their own brand of 90's infused rock has never gone out of favor, and they deliver it with impressive precision both live and on record.Catch Alright Junior at Brainfest on May 25, 2024 at Broken Goblet Brewing. Wheatus will be headlining the show and all proceeds benefit the American Brain Tumor Association.I hope you enjoy this fun diner convo!~ JKF ❤️

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/NAX865. CME/MOC/AAPA credit will be available until December 16, 2024.Shattering the Barriers to Glioblastoma Care: Revolutionary Advances With Innovative Technologies and Modern Systemic Approaches In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Brain Tumor Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Blue Earth Diagnostics and Novocure, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerSteven Brem, MD, has no financial interests/relationships or affiliations in relation to this activity.Faculty/PlannerManmeet S. Ahluwalia, MD, MBA, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AnHeart Therapeutics; Apollomics, Inc.; Autem Therapeutics; Bayer Corporation; Bugworks; Cairn Therapeutics; Caris Life Sciences; Celularity, Inc.; GSK; GT Medical Technologies; Insightec; Janssen Pharmaceuticals, Inc.; Kiyatec Inc.; Modifi Bio; NH TherAguix; Novocure, Inc.; Nuvation Bio, Inc.; Prelude Therapeutics; Pyramid Biosciences; Sumitomo Dainippon Pharma Oncology; The Menarini Group; Tocagen Inc.; Varian Medical Systems, Inc.; ViewRay Technologies, Inc.; Voyager Therapeutics, Inc.; and Xoft, a subsidiary of iCAD, Inc.Grant/Research Support from Seagen Inc.Stock Shareholder in CytoDyn Inc.; MedInnovate Advisors LLC; and MimiVax, LLC.Faculty/PlannerMichelle Kim, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Blue Earth Diagnostics.Patient/PlannerJB Bird has no financial interests/relationships or affiliations in relation to this activity.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/NAX865. CME/MOC/AAPA credit will be available until December 16, 2024.Shattering the Barriers to Glioblastoma Care: Revolutionary Advances With Innovative Technologies and Modern Systemic Approaches In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Brain Tumor Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Blue Earth Diagnostics and Novocure, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerSteven Brem, MD, has no financial interests/relationships or affiliations in relation to this activity.Faculty/PlannerManmeet S. Ahluwalia, MD, MBA, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AnHeart Therapeutics; Apollomics, Inc.; Autem Therapeutics; Bayer Corporation; Bugworks; Cairn Therapeutics; Caris Life Sciences; Celularity, Inc.; GSK; GT Medical Technologies; Insightec; Janssen Pharmaceuticals, Inc.; Kiyatec Inc.; Modifi Bio; NH TherAguix; Novocure, Inc.; Nuvation Bio, Inc.; Prelude Therapeutics; Pyramid Biosciences; Sumitomo Dainippon Pharma Oncology; The Menarini Group; Tocagen Inc.; Varian Medical Systems, Inc.; ViewRay Technologies, Inc.; Voyager Therapeutics, Inc.; and Xoft, a subsidiary of iCAD, Inc.Grant/Research Support from Seagen Inc.Stock Shareholder in CytoDyn Inc.; MedInnovate Advisors LLC; and MimiVax, LLC.Faculty/PlannerMichelle Kim, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Blue Earth Diagnostics.Patient/PlannerJB Bird has no financial interests/relationships or affiliations in relation to this activity.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/NAX865. CME/MOC/AAPA credit will be available until December 16, 2024.Shattering the Barriers to Glioblastoma Care: Revolutionary Advances With Innovative Technologies and Modern Systemic Approaches In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Brain Tumor Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Blue Earth Diagnostics and Novocure, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerSteven Brem, MD, has no financial interests/relationships or affiliations in relation to this activity.Faculty/PlannerManmeet S. Ahluwalia, MD, MBA, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AnHeart Therapeutics; Apollomics, Inc.; Autem Therapeutics; Bayer Corporation; Bugworks; Cairn Therapeutics; Caris Life Sciences; Celularity, Inc.; GSK; GT Medical Technologies; Insightec; Janssen Pharmaceuticals, Inc.; Kiyatec Inc.; Modifi Bio; NH TherAguix; Novocure, Inc.; Nuvation Bio, Inc.; Prelude Therapeutics; Pyramid Biosciences; Sumitomo Dainippon Pharma Oncology; The Menarini Group; Tocagen Inc.; Varian Medical Systems, Inc.; ViewRay Technologies, Inc.; Voyager Therapeutics, Inc.; and Xoft, a subsidiary of iCAD, Inc.Grant/Research Support from Seagen Inc.Stock Shareholder in CytoDyn Inc.; MedInnovate Advisors LLC; and MimiVax, LLC.Faculty/PlannerMichelle Kim, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Blue Earth Diagnostics.Patient/PlannerJB Bird has no financial interests/relationships or affiliations in relation to this activity.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/NAX865. CME/MOC/AAPA credit will be available until December 16, 2024.Shattering the Barriers to Glioblastoma Care: Revolutionary Advances With Innovative Technologies and Modern Systemic Approaches In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Brain Tumor Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Blue Earth Diagnostics and Novocure, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerSteven Brem, MD, has no financial interests/relationships or affiliations in relation to this activity.Faculty/PlannerManmeet S. Ahluwalia, MD, MBA, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AnHeart Therapeutics; Apollomics, Inc.; Autem Therapeutics; Bayer Corporation; Bugworks; Cairn Therapeutics; Caris Life Sciences; Celularity, Inc.; GSK; GT Medical Technologies; Insightec; Janssen Pharmaceuticals, Inc.; Kiyatec Inc.; Modifi Bio; NH TherAguix; Novocure, Inc.; Nuvation Bio, Inc.; Prelude Therapeutics; Pyramid Biosciences; Sumitomo Dainippon Pharma Oncology; The Menarini Group; Tocagen Inc.; Varian Medical Systems, Inc.; ViewRay Technologies, Inc.; Voyager Therapeutics, Inc.; and Xoft, a subsidiary of iCAD, Inc.Grant/Research Support from Seagen Inc.Stock Shareholder in CytoDyn Inc.; MedInnovate Advisors LLC; and MimiVax, LLC.Faculty/PlannerMichelle Kim, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Blue Earth Diagnostics.Patient/PlannerJB Bird has no financial interests/relationships or affiliations in relation to this activity.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/NAX865. CME/MOC/AAPA credit will be available until December 16, 2024.Shattering the Barriers to Glioblastoma Care: Revolutionary Advances With Innovative Technologies and Modern Systemic Approaches In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Brain Tumor Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Blue Earth Diagnostics and Novocure, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerSteven Brem, MD, has no financial interests/relationships or affiliations in relation to this activity.Faculty/PlannerManmeet S. Ahluwalia, MD, MBA, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AnHeart Therapeutics; Apollomics, Inc.; Autem Therapeutics; Bayer Corporation; Bugworks; Cairn Therapeutics; Caris Life Sciences; Celularity, Inc.; GSK; GT Medical Technologies; Insightec; Janssen Pharmaceuticals, Inc.; Kiyatec Inc.; Modifi Bio; NH TherAguix; Novocure, Inc.; Nuvation Bio, Inc.; Prelude Therapeutics; Pyramid Biosciences; Sumitomo Dainippon Pharma Oncology; The Menarini Group; Tocagen Inc.; Varian Medical Systems, Inc.; ViewRay Technologies, Inc.; Voyager Therapeutics, Inc.; and Xoft, a subsidiary of iCAD, Inc.Grant/Research Support from Seagen Inc.Stock Shareholder in CytoDyn Inc.; MedInnovate Advisors LLC; and MimiVax, LLC.Faculty/PlannerMichelle Kim, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Blue Earth Diagnostics.Patient/PlannerJB Bird has no financial interests/relationships or affiliations in relation to this activity.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/NAX865. CME/MOC/AAPA credit will be available until December 16, 2024.Shattering the Barriers to Glioblastoma Care: Revolutionary Advances With Innovative Technologies and Modern Systemic Approaches In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Brain Tumor Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Blue Earth Diagnostics and Novocure, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerSteven Brem, MD, has no financial interests/relationships or affiliations in relation to this activity.Faculty/PlannerManmeet S. Ahluwalia, MD, MBA, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AnHeart Therapeutics; Apollomics, Inc.; Autem Therapeutics; Bayer Corporation; Bugworks; Cairn Therapeutics; Caris Life Sciences; Celularity, Inc.; GSK; GT Medical Technologies; Insightec; Janssen Pharmaceuticals, Inc.; Kiyatec Inc.; Modifi Bio; NH TherAguix; Novocure, Inc.; Nuvation Bio, Inc.; Prelude Therapeutics; Pyramid Biosciences; Sumitomo Dainippon Pharma Oncology; The Menarini Group; Tocagen Inc.; Varian Medical Systems, Inc.; ViewRay Technologies, Inc.; Voyager Therapeutics, Inc.; and Xoft, a subsidiary of iCAD, Inc.Grant/Research Support from Seagen Inc.Stock Shareholder in CytoDyn Inc.; MedInnovate Advisors LLC; and MimiVax, LLC.Faculty/PlannerMichelle Kim, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Blue Earth Diagnostics.Patient/PlannerJB Bird has no financial interests/relationships or affiliations in relation to this activity.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

In this episode brain tumor blogger and advocate, Wendy Santana returns to share how helping others ended up playing a major role in her own healing. She shares how sharing her story has helped her and other globally. She talks about how she utilizes her blog, “2nd Chance 2 Live” as a resource and a platform to elevate other brain tumor and cancer survivors. She provides details about the four incredible individuals she has met through her interviews and awareness efforts who have since lost their lives to the most aggressive form of brain cancer, GBM. This leads to a discussion about the need for breakthroughs since there isn't a cure for brain cancer. Wendy and Todd (along with other brain tumor survivors) are representing team “2nd Chance 2 Live” for the upcoming BT5K (Breakthrough for Brain Tumors 5K run/walk) on 11/5/22. The goal is to raise money for the American Brain Tumor Association to continue providing free patient/caregiver support and information along with research grants around the country (and beyond). Since 2006 the BT5K events have raised over $33 million for brain tumor research and patient support services. Check it out! “2nd Chance 2 Live” team page: https://give.abta.org/team/416649 Todd's BT5K fundraising page: https://give.abta.org/fundraiser/4226329 Wendy's BT5K fundraising page: https://give.abta.org/fundraiser/3795198 Links to mentions during the podcast Wendy's website: https://2ndchance2live.com/ Wendy's resources: https://2ndchance2live.com/resources/ Wendy's suggested reading: https://2ndchance2live.com/suggestedreading/ Link to the A Face of Strength campaign: https://2ndchance2live.com/afaceofstrength/ Email: Wendy.2ndChance2Live@gmail.com Follow Wendy's blog on social media Facebook: https://www.facebook.com/2ndChance2Live Instagram (new account): https://www.instagram.com/2nd.chance.2.live/ Twitter: https://twitter.com/2nd_Chance2Live

Hi everyone! This is Kelly - your Nutrition Coach and Brain Health Professional on a mission to teach you how to get a better brain!We have been so focused on supporting your brain health and mental wellness for so long that it may be time to do something a little different… introduce you to your brain!How well do you know your brain? Do you know the main parts of the brain? Are you aware that each part is responsible for something different? Moreover, did you realize that each part of the brain has different nutritional requirements?Keep listening for your personal crash course about the brain - Neuroanatomy 101.How to get more oxygen to the brain Antioxidants: Foods vs Supplements Brain inflammation: What it is and what you can do about itHow Omega 3 Fatty Acids Can Reduce Your Risk for Alzheimer'sHow to Banish Brain Fog: 8 Ways to Regain Clarity and Age GracefullyWhich neurotransmitters are related to mental health https://linktr.ee/kellyaiello |Buy me a coffee

This week we speak with Bill Wallace, who founded the Sunlight On Chrome Initiative to raise money for the American Brain Tumor Association. Bill talks about how Neil Peart inspired his love of motorcycling, the beginnings of his fundraising efforts, and how Rush fans everywhere can take part in the Sunlight On Chrome Initiative by doing the most excellent thing you can do on Friday, July 29.

Tune in on Monday, 6/13/22 at 6:30am EST, for a brand new episode of The Doctor Whisperer Show featuring Preston R Scott! ▪︎ ▪︎ ▪︎ ︎ ABOUT OUR GUEST: Preston Scott holds a Juris Masters degree in Financial Regulation and Compliance from FSU School of Law. He has served in the Banking industry in various roles over the past 10 years working for some of the most progressive community banks in the Tampa Bay area including C1 Bank and Pilot Bank. Prior to his banking career he served as a Lancome Paris Business Manager at various retailers and was featured as a featured makeup artist throughout the state of Florida. He is a master of bringing a brand and its mission to the forefront of a community through representation and building employee engagement. Having had the pleasure of working closely with incredible community Leaders and industry trailblazers,Preston has earned the respect and trust needed to assist in major community initiatives. While his role has often been supportive, his work was vital in the success of these initiatives. Preston has served as the Marketing/PR Chair of the 2019 American Cancer Society's Cattle Barons' Ball, an initiative that raised $500,000 for our community. His community involvement includes organizations such as the Outback Bowl, American Heart Association, American Brain Tumor Association, Dress for Success, Working Women of Tampa Bay, and the Girl Scout's WCF Camp CEO, USF WLP. Preston serves as an Area Board Advisory member for United Way Suncoast and serves on its Sustainability and Innovation Committee. Preston is a 2019 Leadership Tampa Bay alumni. In 2020 he served on the Board of Advisors for Digital Marketing at USF and as a Dean appointed mentor for the Innovative Scholars Program at USF St. Pete. Preston is very passionate about mental health awareness and self-care. In his spare time, Preston enjoys catching the stunning sunsets and moon rises during long walks on the Courtney Campbell Causeway, spending quality time with his family & and staying current with the latest news in Auto Journalism. His favorite podcasts are Brene Brown's Dare to Lead and Unlocking Us. ▪︎ ▪︎ ▪︎ ︎ As always, thank you to our incredible sponsor, TieTechnology, for sponsoring the show! --- Send in a voice message: https://anchor.fm/thedoctorwhisperer/message

Episode 133 – FMC Runs Chicago: Chapter 5 Pete seems off at the beginning and then seems to talk a ton. Dave gives us insight into his week and overall outlook from now until the race. Pete may be a bit confrontational. Dave takes it in stride. In other words, about what you'd expect. RunningWarriorSarah is the first to answer the challenge and signed up for the Chicago Marathon while raising money for the American Brain Tumor Association. Check out her Instagram, podcast, and her charity link! The guys seem to have a track and a plan. Will they stick to it? Is Pete too hard on Dave in this episode? What questions do you have for the guys? Let them know! Don't forget to take a look at Dave's fundraising page and give a few bucks if you can. Now, get out there and #bebettertoday! This episode is sponsored by The No Fear Project podcast, the Be Better Today podcast, and That Wine Pod. Subscribe now in your favorite podcast app! Join The No Fear Project on Facebook or shoot Pete a note for more information.   Listen, subscribe, share, rate & review! Please subscribe to the podcast and leave us a review on iTunes/Apple Podcasts, Spotify, Google Play, Podbean, Stitcher, or in your favorite podcast app! Find FatMan Chronicles at: Fatmanchronicles.com Facebook.com/fatmanstories Twitter & Instagram - @fatmanstories Email – fatmanchronicles@outlook.com Music – “You Got Me Wrong” by Sifar Copyright 2022 Paragon Media – All Rights Reserved

This show begins with a nod to 5 Georgia Bulldog football players who are taking advantage of the new NIL (Name Image and Likeness) rule, to raise money for charity. They founded the DGD Fund, which stands for Damn Good Dawgs, to raise awareness and money for The American Brain Tumor Association, Happy Feet day […]

Today we learn about a former NASCAR driver who is working with the American Brain Tumor Association to help those most in need, as well as exploring Grand Teton National Park.

In this episode Brandon Starkoff, CEO of Transparent Partners, shares his experience working with companies to help them transform their brands. Transparent Partners is an independent marketing technology and data consultancy. Brandon is a 10 year cancer survivor who shares how that experience has shaped his appreciation for his work, impact on people and his clients, and his ability to continue his work with the cancer community. Words of wisdom: Reality check your situation and remember the people in your life who support and champion you. About Brandon Starkoff: Brandon is constantly helping organizations re-imagine and adapt to support their customers. He is an experienced global leader responsible for building customized and transformative marketing solutions to generate growth for Fortune 1,000 companies. A professional with strong expertise in strategy and digitally-driven capabilities, he developed and led activation of a new agency and brand operating vision and models to inspire new data-driven capabilities, cultivate top global talent and deliver against growth objectives. Over the course of his 21 year career, Brandon has formed trusted partnerships with c-suite executives to introduce and implement several new methods of marketing technology and data infrastructure design, integrated partnerships and measurement solutions to improve speed to market, product innovation and customer experiences leading to impact for his client businesses. He also spends his time as a Board Member for the American Brain Tumor Association and supports his annual "Cater To The Cure" fundraiser for Brain Cancer research. As a 10 year cancer survivor and fighter, Brandon is passionate in helping others stay motivated through their battle and ensures they have the resources they need to manage their care. To connect to Bradon Starkoff and Transparent Partners Twitter: @bstarkoff LinkedIn: https://www.linkedin.com/in/brandon-starkoff-b624192/ Company LinkedIn: https://www.linkedin.com/company/transparent-partners/mycompany/?viewAsMember=true Company LinkedIn Handle: @Transparent. To connect to Simone and Your Choice Coach: www.YourChoiceCoach.com www.linkedin.com/in/simonesloan https://yourchoicecoach.com Twitter: @AimInspireGrow Facebook: https://www.facebook.com/YourBusinessGreatness YouTube: Your Business Greatness

This week we have a very special guest, Alex Stewart AKA @sassyconfetti, a blogger, bedwine founder, and co-host of the podcast Swipe Fat. We talk about Dido, the Queen of Carthage that flees her brother and gets a bunch of great land using an ox hide. Her legacy, though, isn't all positive. The non-profit pairing this week is the American Brain Tumor Association (https://www.abta.org/). We will be making a donation, and we hope you do too. Hosted by Rachael Marr and Mindy Scott. Audio production and music by Aaron Crossland. Researched and written by Dr. Lauren Crossland-Marr. Episode music by F. Laroque, available at flarocque.bandcamp.com Ad Music by Chris Zabriskie. Please consider supporting us! Leave us a rating or review on your favorite podcasting app, or donate a little something by going to this link: https://anchor.fm/femlore-podcast/support --- Support this podcast: https://anchor.fm/femlore-podcast/support

In this episode, Dr. Kesari talks about his 20 years of working with patients suffering a deadly disease. He speaks about how his patients and their families are like his own and how his connection to them gave him a deep understanding of living and dying.Dr. Santosh Kesari is a board-certified neurologist and neuro-oncologist and is currently Chair and Professor, Department of Translational Neurosciences and Neurotherapeutics, Saint John’s Cancer Institute. He is also Director of Neuro-oncology at Pacific Neuroscience Institute, Providence Saint John’s Health Center and Providence Little Company of Mary Medical Center Torrance and leads the Pacific Neuroscience Research Center at Pacific Neuroscience Institute.Dr. Kesari is ranked among the top 1% of neuro-oncologists and neurologists in the nation, according to Castle Connolly Medical Ltd and an internationally recognized scientist and clinician. He is a winner of an Innovation Award by the San Diego Business Journal. He is on the advisory board of American Brain Tumor Association, San Diego Brain Tumor Foundation, Chris Elliott Fund, Nicolas Conor Institute, Voices Against Brain Cancer, and Philippine Brain Tumor Alliance. He has been the author of over 250 scientific publications, reviews, or books. He is the inventor on several patents and patent applications, and founder and advisor to many cancer and neurosciences focused biotech startups. In addition, he is a member of the Los Angeles Biomedical Research Institute.Dr. Kesari has had a long-standing interest in cancer stem cells and studies their role in the formation of brain tumors and resistance to treatment. He believes that in order to cure patients with brain tumors we first need to gain a better molecular and biological understanding of the disease. A physician/scientist, Kesari harnesses his experience in surgery, chemotherapy, immunotherapy, radiation therapy and novel devices to help develop Precision Therapeutic Strategies that will advance medicine to a new stage in the battle against brain tumors and eradicate the disease.HighlightsDr. Kesari graduated from University of Pennsylvania, School of Arts and Sciences in 1992 and earned a PhD degree in molecular biology and a MD from the University of Pennsylvania, School of Medicine.He completed his residency in neurology at the Massachusetts General Hospital/Brigham and Women’s Hospital/Harvard Medical School and his neuro-oncology fellowship at the Dana-Farber Cancer Institute in Boston. He was previously assistant professor of neurology at Harvard Medical School/Dana-Farber Cancer Institute/Brigham and Women’s Hospital and then professor of neurosciences at UC San Diego. He is a member of the Society of Neuro-Oncology, American Society of Clinical Oncology, Indian Society of Neuro-Oncology, American Neurological Association, and American Academy of Neurology.Support the show (https://healgrief.org/donations/)

Go online to PeerView.com/CBA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As new therapeutic strategies are explored and validated, oncologists have more effective treatments to offer their patients with glioblastoma, the most common and lethal brain tumor in adults. Tumor treating fields (TTFields), a novel modality, has been an important step forward in improving outcomes in glioblastoma and has increased the armamentarium beyond surgical resection, radiation therapy, and chemotherapy. Moreover, targeted therapies continue to demonstrate promising results. Join PeerView and the American Brain Tumor Association to learn about the latest evidence on TTFields and other treatment strategies, including targeted therapies, such as antiangiogenic antibodies and multikinase and TRK inhibitors, that are being explored in glioblastoma. In this CME-certified activity, a panel of experts in neuro-oncology will provide insights on the future of glioblastoma management, strategies for integrating therapeutic advances into the clinic, and approaches to personalizing care, including the considerations of clinical trial enrollment, for patients with glioblastoma. Upon completion of this activity, participants should be better able to: Evaluate the rationale and pivotal clinical evidence on guideline-recommended treatment strategies, such as tumor treating fields and multikinase and TRK inhibitors, for patients with newly diagnosed and recurrent glioblastoma, Review the latest safety and efficacy evidence and ongoing clinical trials investigating novel agents, including immune checkpoint, multikinase, gene fusion, proteasome, PARP, EGFR, and nuclear export inhibitors, for the therapeutic management of glioblastoma, Develop safe and effective personalized treatment plans, including consideration of clinical trial enrollment, for patients with newly diagnosed and recurrent glioblastoma.

Go online to PeerView.com/CBA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As new therapeutic strategies are explored and validated, oncologists have more effective treatments to offer their patients with glioblastoma, the most common and lethal brain tumor in adults. Tumor treating fields (TTFields), a novel modality, has been an important step forward in improving outcomes in glioblastoma and has increased the armamentarium beyond surgical resection, radiation therapy, and chemotherapy. Moreover, targeted therapies continue to demonstrate promising results. Join PeerView and the American Brain Tumor Association to learn about the latest evidence on TTFields and other treatment strategies, including targeted therapies, such as antiangiogenic antibodies and multikinase and TRK inhibitors, that are being explored in glioblastoma. In this CME-certified activity, a panel of experts in neuro-oncology will provide insights on the future of glioblastoma management, strategies for integrating therapeutic advances into the clinic, and approaches to personalizing care, including the considerations of clinical trial enrollment, for patients with glioblastoma. Upon completion of this activity, participants should be better able to: Evaluate the rationale and pivotal clinical evidence on guideline-recommended treatment strategies, such as tumor treating fields and multikinase and TRK inhibitors, for patients with newly diagnosed and recurrent glioblastoma, Review the latest safety and efficacy evidence and ongoing clinical trials investigating novel agents, including immune checkpoint, multikinase, gene fusion, proteasome, PARP, EGFR, and nuclear export inhibitors, for the therapeutic management of glioblastoma, Develop safe and effective personalized treatment plans, including consideration of clinical trial enrollment, for patients with newly diagnosed and recurrent glioblastoma.

Go online to PeerView.com/CBA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As new therapeutic strategies are explored and validated, oncologists have more effective treatments to offer their patients with glioblastoma, the most common and lethal brain tumor in adults. Tumor treating fields (TTFields), a novel modality, has been an important step forward in improving outcomes in glioblastoma and has increased the armamentarium beyond surgical resection, radiation therapy, and chemotherapy. Moreover, targeted therapies continue to demonstrate promising results. Join PeerView and the American Brain Tumor Association to learn about the latest evidence on TTFields and other treatment strategies, including targeted therapies, such as antiangiogenic antibodies and multikinase and TRK inhibitors, that are being explored in glioblastoma. In this CME-certified activity, a panel of experts in neuro-oncology will provide insights on the future of glioblastoma management, strategies for integrating therapeutic advances into the clinic, and approaches to personalizing care, including the considerations of clinical trial enrollment, for patients with glioblastoma. Upon completion of this activity, participants should be better able to: Evaluate the rationale and pivotal clinical evidence on guideline-recommended treatment strategies, such as tumor treating fields and multikinase and TRK inhibitors, for patients with newly diagnosed and recurrent glioblastoma, Review the latest safety and efficacy evidence and ongoing clinical trials investigating novel agents, including immune checkpoint, multikinase, gene fusion, proteasome, PARP, EGFR, and nuclear export inhibitors, for the therapeutic management of glioblastoma, Develop safe and effective personalized treatment plans, including consideration of clinical trial enrollment, for patients with newly diagnosed and recurrent glioblastoma.

Go online to PeerView.com/CBA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As new therapeutic strategies are explored and validated, oncologists have more effective treatments to offer their patients with glioblastoma, the most common and lethal brain tumor in adults. Tumor treating fields (TTFields), a novel modality, has been an important step forward in improving outcomes in glioblastoma and has increased the armamentarium beyond surgical resection, radiation therapy, and chemotherapy. Moreover, targeted therapies continue to demonstrate promising results. Join PeerView and the American Brain Tumor Association to learn about the latest evidence on TTFields and other treatment strategies, including targeted therapies, such as antiangiogenic antibodies and multikinase and TRK inhibitors, that are being explored in glioblastoma. In this CME-certified activity, a panel of experts in neuro-oncology will provide insights on the future of glioblastoma management, strategies for integrating therapeutic advances into the clinic, and approaches to personalizing care, including the considerations of clinical trial enrollment, for patients with glioblastoma. Upon completion of this activity, participants should be better able to: Evaluate the rationale and pivotal clinical evidence on guideline-recommended treatment strategies, such as tumor treating fields and multikinase and TRK inhibitors, for patients with newly diagnosed and recurrent glioblastoma, Review the latest safety and efficacy evidence and ongoing clinical trials investigating novel agents, including immune checkpoint, multikinase, gene fusion, proteasome, PARP, EGFR, and nuclear export inhibitors, for the therapeutic management of glioblastoma, Develop safe and effective personalized treatment plans, including consideration of clinical trial enrollment, for patients with newly diagnosed and recurrent glioblastoma.

Go online to PeerView.com/CBA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As new therapeutic strategies are explored and validated, oncologists have more effective treatments to offer their patients with glioblastoma, the most common and lethal brain tumor in adults. Tumor treating fields (TTFields), a novel modality, has been an important step forward in improving outcomes in glioblastoma and has increased the armamentarium beyond surgical resection, radiation therapy, and chemotherapy. Moreover, targeted therapies continue to demonstrate promising results. Join PeerView and the American Brain Tumor Association to learn about the latest evidence on TTFields and other treatment strategies, including targeted therapies, such as antiangiogenic antibodies and multikinase and TRK inhibitors, that are being explored in glioblastoma. In this CME-certified activity, a panel of experts in neuro-oncology will provide insights on the future of glioblastoma management, strategies for integrating therapeutic advances into the clinic, and approaches to personalizing care, including the considerations of clinical trial enrollment, for patients with glioblastoma. Upon completion of this activity, participants should be better able to: Evaluate the rationale and pivotal clinical evidence on guideline-recommended treatment strategies, such as tumor treating fields and multikinase and TRK inhibitors, for patients with newly diagnosed and recurrent glioblastoma, Review the latest safety and efficacy evidence and ongoing clinical trials investigating novel agents, including immune checkpoint, multikinase, gene fusion, proteasome, PARP, EGFR, and nuclear export inhibitors, for the therapeutic management of glioblastoma, Develop safe and effective personalized treatment plans, including consideration of clinical trial enrollment, for patients with newly diagnosed and recurrent glioblastoma.

Go online to PeerView.com/CBA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As new therapeutic strategies are explored and validated, oncologists have more effective treatments to offer their patients with glioblastoma, the most common and lethal brain tumor in adults. Tumor treating fields (TTFields), a novel modality, has been an important step forward in improving outcomes in glioblastoma and has increased the armamentarium beyond surgical resection, radiation therapy, and chemotherapy. Moreover, targeted therapies continue to demonstrate promising results. Join PeerView and the American Brain Tumor Association to learn about the latest evidence on TTFields and other treatment strategies, including targeted therapies, such as antiangiogenic antibodies and multikinase and TRK inhibitors, that are being explored in glioblastoma. In this CME-certified activity, a panel of experts in neuro-oncology will provide insights on the future of glioblastoma management, strategies for integrating therapeutic advances into the clinic, and approaches to personalizing care, including the considerations of clinical trial enrollment, for patients with glioblastoma. Upon completion of this activity, participants should be better able to: Evaluate the rationale and pivotal clinical evidence on guideline-recommended treatment strategies, such as tumor treating fields and multikinase and TRK inhibitors, for patients with newly diagnosed and recurrent glioblastoma, Review the latest safety and efficacy evidence and ongoing clinical trials investigating novel agents, including immune checkpoint, multikinase, gene fusion, proteasome, PARP, EGFR, and nuclear export inhibitors, for the therapeutic management of glioblastoma, Develop safe and effective personalized treatment plans, including consideration of clinical trial enrollment, for patients with newly diagnosed and recurrent glioblastoma.

Have you ever tried to tell your story while in the middle of it? Seeing the light and lessons can be challenging in hindsight let alone while living it. Ruth Kavanagh who is currently fighting, surviving, and thriving with brain cancer shares her message of hope, courage, and strength in the midst of metastasis. She is a true warrior advocating for others even while she is in the throes of her own treatment. Our souls were touched and tissues were wet during this recording. Be prepared for tears, laughs, goosebumps, and inspiration. We caution you that this is an emotionally powerful episode, please be in a safe space while listening.   In this episode: Traumatic vs. Acquired Brain Injury Traumatic- from an outside injury or force, i.e. car crash, hitting head, concussion Acquired- an internal factor, i.e. lack of oxygen, aneurysm, stroke, infection, brain tumor Ruth Kavanaugh's story Thriver, survivor, fighter!  Listen to your body, it will tell you if something is wrong Anaplastic Ependymoma: one of the rarest forms of brain tumor, only about 2% of brain tumors are this type. It is cancerous and extremely aggressive.  Because it is so rare there is little research or treatment options. Ruth set her mind that she will get through this If you go online, make sure it is a reputable site (see below for suggestions) Radiation therapy Caused extreme fatigue Life after treatment: too tired to do anything and left to your own thoughts.  Can be a very dark time.  Taking care of your emotional and mental health Remove the stigma.  There is zero harm in seeing a counselor.  Only good will come from it.  You've got nothing to lose! Important to “date around” and find a counselor/psychiatrist who is the right fit The cancer chaos “Scan-xiety” is a real thing.  Cancer survivors, you are not alone when you feel anxious about upcoming scans Recurrence  More discussions in tumor boards, consultations, surgeries, and therapies Stereotactic radiotherapy Avastin- side effects bleeding and prevention of wound healing Infection Loss during hard times Revisional surgeries Metastasis, only 25 cases known in the world that spread the way Ruthie's has More chemo Lessons for healthcare professionals: listen to your patient, don't make pre-judgements, be very cognizant of where the patient is now rather than basing all judgement on your past experience with the patient, sitting with a patient lowers the power divide (standing over a patient is very intimidating and strengthens a patriarchal model of care), respect the person as a person (not just a condition) Self-advocacy is advocacy for those who don't have a voice.  By standing up, telling your story, and advocating for better care; you can serve to stand up for those who can't do it for themselves and help others.  “I'm tired, but there is hope!” Strength, courage, and hope through extended trauma “There's always hope.  It doesn't necessarily mean that there is going to be a magical cure.  Look for it in the little things.” Hope can be finally being able to eat real food, getting out of bed, hoping for peace and being surrounded by loved ones Find your tribe--find someone who has been through your experience To get connected with others and reputable resources:  National Brain Tumor Society,  American Brain Tumor Association,  First Descents- free camps for young adults with brain tumors  or MS Epic Experience: cancer camp for adults American Cancer Society:https://www.cancer.org/ Connect with the social worker in the hospital or cancer center to get more resources Links to any resources mentioned Brain Injury Association of America: https://www.biausa.org/ (https://www.biausa.org/)  National Brain Tumor Society: https://braintumor.org/ (https://braintumor.org/)  National Institute of Health (NIH): https://www.nih.gov/...

Today on the show the boys wrap up some voicemails from our Farewell to a King tribute. Thanks to everyone who called in and shared in our grief. We are proud of the way the Rush community has come together during this painful chapter in our lives. Also, we are re-releasing our most downloaded episode of the year as a way of introducing our new listeners to the normal format of the show, and also to prepare you for a monster announcement from our friends at Overtime Angels. Follow the show online: Twitter: @Pwavespod Instagram and Facebook: @PermanentWavesPodcast PermanentWavesPodcast.com For more information on the ABTA, click here: The American Brain Tumor Association

Go online to PeerView.com/DRB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The advent of the fourth treatment modality, tumor treating fields (TTFields), and ongoing research on novel systemic agents are continuing to improve clinical outcomes for patients with glioblastoma. In this activity, based on a recent live symposium planned in collaboration with the American Brain Tumor Association and held during the 24th Annual Meeting of the Society for Neuro-Oncology, neuro-oncology experts discuss cutting-edge advancements with TTFields therapy and the future outlook on novel targeted agents for patients with glioblastoma. Additionally, the faculty share stories about real patients to highlight how scientific advancements and clinical data translate into personalized care. Upon completion of this activity, participants should be better able to: Summarize the biologic rationale of TTFields, immunotherapy, multikinase and TRK inhibitors, among other drug classes for the treatment of glioblastoma, Assess the latest clinical evidence on currently available treatment strategies, such as TTFields and targeted TRK inhibitors, for newly diagnosed and recurrent glioblastoma, Review recent safety and efficacy evidence on novel agents under investigation, including immune checkpoint and multikinase inhibitors, for the therapeutic management of glioblastoma, Develop personalized treatment plans for patients with glioblastoma (both newly diagnosed and recurrent), including the consideration of enrolling in clinical trials

Go online to PeerView.com/DRB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The advent of the fourth treatment modality, tumor treating fields (TTFields), and ongoing research on novel systemic agents are continuing to improve clinical outcomes for patients with glioblastoma. In this activity, based on a recent live symposium planned in collaboration with the American Brain Tumor Association and held during the 24th Annual Meeting of the Society for Neuro-Oncology, neuro-oncology experts discuss cutting-edge advancements with TTFields therapy and the future outlook on novel targeted agents for patients with glioblastoma. Additionally, the faculty share stories about real patients to highlight how scientific advancements and clinical data translate into personalized care. Upon completion of this activity, participants should be better able to: Summarize the biologic rationale of TTFields, immunotherapy, multikinase and TRK inhibitors, among other drug classes for the treatment of glioblastoma, Assess the latest clinical evidence on currently available treatment strategies, such as TTFields and targeted TRK inhibitors, for newly diagnosed and recurrent glioblastoma, Review recent safety and efficacy evidence on novel agents under investigation, including immune checkpoint and multikinase inhibitors, for the therapeutic management of glioblastoma, Develop personalized treatment plans for patients with glioblastoma (both newly diagnosed and recurrent), including the consideration of enrolling in clinical trials

Go online to PeerView.com/DRB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The advent of the fourth treatment modality, tumor treating fields (TTFields), and ongoing research on novel systemic agents are continuing to improve clinical outcomes for patients with glioblastoma. In this activity, based on a recent live symposium planned in collaboration with the American Brain Tumor Association and held during the 24th Annual Meeting of the Society for Neuro-Oncology, neuro-oncology experts discuss cutting-edge advancements with TTFields therapy and the future outlook on novel targeted agents for patients with glioblastoma. Additionally, the faculty share stories about real patients to highlight how scientific advancements and clinical data translate into personalized care. Upon completion of this activity, participants should be better able to: Summarize the biologic rationale of TTFields, immunotherapy, multikinase and TRK inhibitors, among other drug classes for the treatment of glioblastoma, Assess the latest clinical evidence on currently available treatment strategies, such as TTFields and targeted TRK inhibitors, for newly diagnosed and recurrent glioblastoma, Review recent safety and efficacy evidence on novel agents under investigation, including immune checkpoint and multikinase inhibitors, for the therapeutic management of glioblastoma, Develop personalized treatment plans for patients with glioblastoma (both newly diagnosed and recurrent), including the consideration of enrolling in clinical trials

Go online to PeerView.com/DRB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The advent of the fourth treatment modality, tumor treating fields (TTFields), and ongoing research on novel systemic agents are continuing to improve clinical outcomes for patients with glioblastoma. In this activity, based on a recent live symposium planned in collaboration with the American Brain Tumor Association and held during the 24th Annual Meeting of the Society for Neuro-Oncology, neuro-oncology experts discuss cutting-edge advancements with TTFields therapy and the future outlook on novel targeted agents for patients with glioblastoma. Additionally, the faculty share stories about real patients to highlight how scientific advancements and clinical data translate into personalized care. Upon completion of this activity, participants should be better able to: Summarize the biologic rationale of TTFields, immunotherapy, multikinase and TRK inhibitors, among other drug classes for the treatment of glioblastoma, Assess the latest clinical evidence on currently available treatment strategies, such as TTFields and targeted TRK inhibitors, for newly diagnosed and recurrent glioblastoma, Review recent safety and efficacy evidence on novel agents under investigation, including immune checkpoint and multikinase inhibitors, for the therapeutic management of glioblastoma, Develop personalized treatment plans for patients with glioblastoma (both newly diagnosed and recurrent), including the consideration of enrolling in clinical trials

Go online to PeerView.com/DRB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The advent of the fourth treatment modality, tumor treating fields (TTFields), and ongoing research on novel systemic agents are continuing to improve clinical outcomes for patients with glioblastoma. In this activity, based on a recent live symposium planned in collaboration with the American Brain Tumor Association and held during the 24th Annual Meeting of the Society for Neuro-Oncology, neuro-oncology experts discuss cutting-edge advancements with TTFields therapy and the future outlook on novel targeted agents for patients with glioblastoma. Additionally, the faculty share stories about real patients to highlight how scientific advancements and clinical data translate into personalized care. Upon completion of this activity, participants should be better able to: Summarize the biologic rationale of TTFields, immunotherapy, multikinase and TRK inhibitors, among other drug classes for the treatment of glioblastoma, Assess the latest clinical evidence on currently available treatment strategies, such as TTFields and targeted TRK inhibitors, for newly diagnosed and recurrent glioblastoma, Review recent safety and efficacy evidence on novel agents under investigation, including immune checkpoint and multikinase inhibitors, for the therapeutic management of glioblastoma, Develop personalized treatment plans for patients with glioblastoma (both newly diagnosed and recurrent), including the consideration of enrolling in clinical trials

Go online to PeerView.com/DRB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The advent of the fourth treatment modality, tumor treating fields (TTFields), and ongoing research on novel systemic agents are continuing to improve clinical outcomes for patients with glioblastoma. In this activity, based on a recent live symposium planned in collaboration with the American Brain Tumor Association and held during the 24th Annual Meeting of the Society for Neuro-Oncology, neuro-oncology experts discuss cutting-edge advancements with TTFields therapy and the future outlook on novel targeted agents for patients with glioblastoma. Additionally, the faculty share stories about real patients to highlight how scientific advancements and clinical data translate into personalized care. Upon completion of this activity, participants should be better able to: Summarize the biologic rationale of TTFields, immunotherapy, multikinase and TRK inhibitors, among other drug classes for the treatment of glioblastoma, Assess the latest clinical evidence on currently available treatment strategies, such as TTFields and targeted TRK inhibitors, for newly diagnosed and recurrent glioblastoma, Review recent safety and efficacy evidence on novel agents under investigation, including immune checkpoint and multikinase inhibitors, for the therapeutic management of glioblastoma, Develop personalized treatment plans for patients with glioblastoma (both newly diagnosed and recurrent), including the consideration of enrolling in clinical trials

Join us this week on Christian Devotions SPEAK UP! when Scott shares the road of cancer survival with author and Boot Camp graduate Venita McCart. Venita McCart began her ministry of encouraging cancer patients in 2004 and founded Faith Force Cancer Support Group Ministry in 2005. According to statistics at the time of her cancer diagnosis in 2000, her prognosis for survival was grim. Because of her passion for Christ and a call to serve those dealing with cancer, she has been in contact with countless cancer patients and loved ones through her care group, personal contacts, writing, and speaking. Her goal is to encourage cancer patients and their loved ones from the perspective of faith.  Venita serves as the Support Group Ministry Director in her church. She is an award-winning volunteer with the American Cancer Society and a member of the American Brain Tumor Association. Venita is a member of Word Weavers, has been published with Christian Devotions.us, and writes the material for her Faith Force Support Group Ministry meetings. Her favorite earthly joy is to spend time with her husband Gary, their two adult children (and spouses), and her six grandchildren. Her first book, “It's Cancer” – Finding Help and Hope on the Road to Recovery, was written to encourage cancer patients, survivors, and loved ones. It was released by Lighthouse Publishing of the Carolinas and is available on Amazon. Venita and Gary live in central Illinois. She can be reached at venitamccart@gmail.com.

Join us this week on Christian Devotions SPEAK UP! when Scott shares the road of cancer survival with author and Boot Camp graduate Venita McCart. Venita McCart began her ministry of encouraging cancer patients in 2004 and founded Faith Force Cancer Support Group Ministry in 2005. According to statistics at the time of her cancer diagnosis in 2000, her prognosis for survival was grim. Because of her passion for Christ and a call to serve those dealing with cancer, she has been in contact with countless cancer patients and loved ones through her care group, personal contacts, writing, and speaking. Her goal is to encourage cancer patients and their loved ones from the perspective of faith.  Venita serves as the Support Group Ministry Director in her church. She is an award-winning volunteer with the American Cancer Society and a member of the American Brain Tumor Association. Venita is a member of Word Weavers, has been published with Christian Devotions.us, and writes the material for her Faith Force Support Group Ministry meetings. Her favorite earthly joy is to spend time with her husband Gary, their two adult children (and spouses), and her six grandchildren. Her first book, “It's Cancer” – Finding Help and Hope on the Road to Recovery, was written to encourage cancer patients, survivors, and loved ones. It was released by Lighthouse Publishing of the Carolinas and is available on Amazon. Venita and Gary live in central Illinois. She can be reached at venitamccart@gmail.com.